Invention Grant
US08389736B2 Compounds having activity in correcting mutant-CFTR processing and uses thereof
有权
具有校正突变体CFTR加工活性的化合物及其用途
- Patent Title: Compounds having activity in correcting mutant-CFTR processing and uses thereof
- Patent Title (中): 具有校正突变体CFTR加工活性的化合物及其用途
-
Application No.: US12682428Application Date: 2008-09-05
-
Publication No.: US08389736B2Publication Date: 2013-03-05
- Inventor: Mark J. Kurth , Alan S. Verkman
- Applicant: Mark J. Kurth , Alan S. Verkman
- Applicant Address: US CA Oakland
- Assignee: The Regents of the University of California
- Current Assignee: The Regents of the University of California
- Current Assignee Address: US CA Oakland
- Agency: Bozicevic, Field & Francis LLP
- Agent Rudy J. Ng; Carol L. Francis
- International Application: PCT/US2008/075503 WO 20080905
- International Announcement: WO2009/051909 WO 20090423
- Main IPC: C07D513/14
- IPC: C07D513/14 ; A61K31/425
Abstract:
The invention provides compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The compositions pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The compositions and pharmaceutical preparations of the invention may comprise one or more bithiazole-containing compounds of the invention, or an analog or derivative thereof.
Public/Granted literature
- US20100273839A1 Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof Public/Granted day:2010-10-28
Information query
